

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:)
Marc ALIZON et al.) Group Art Unit: 1637
Application Ser. No.: 08/475,822) Examiner: Jeffrey N. FREDMAN
Filed: June 7, 1995	, Confirmation No.: 4214)
	,

For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID LAV GENOMIC RNA

ENCODED BY GAID EAV GENOMIC KI

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REQUEST TO CORRECT INVENTORSHIP

Pursuant to 37 C.F.R. § 1.48, applicants request that the inventorship in this application be corrected as follows.

Pursuant to 37 C.F.R. § 1.48 (b), please delete the following inventors from this application:

Marc Alizon,
Pierre Sonigo,
Simon Wain-Hobson,
Stewart Cole, and
Oliver Danos.

06/06/2006 SZEWDIE1 00000025 08475822

05 FC:1464 130.00 OP

Prosecution of this application has resulted in amendment of the claims so that the above-named inventors' invention is no longer being claimed in this application.

Pursuant to 37 C.F.R. § 1.48 (c), please add the following inventors to this application:

Robert C. Gallo,
Milkulas Popovic,
Mangalasseril G. Sarngadharan,
Solange Chamaret,
Claudine Axler-Bin,
Francoise Rey,
Marie-Therese Nugeyre,
Jacqueline Gruest,
Charles Dauget,
Willy Rozenbaum,
Christine Rouzioux,
Francoise Brun-Vezinet,
Luc Montagnier,
Jean-Claude Chermann, and
Francoise Barre-Sinoussi.

The addition of the above-named inventors is necessitated by amendment of the claims during prosecution of this application.

A statement from each person being added as an inventor that the addition is necessitated by amendment of the claims and that the inventorship error occurred without deceptive intent is enclosed.

A Declaration by each of the actual inventors is enclosed. One copy of the application is enclosed although each Declaration was attached to a copy of the application when it was executed. The duplicate copies of the application have been removed to reduce the size of the submission, but will be provided by applicants if the Examiner requires them.

The written consent of each of the assignees is enclosed.

A check for \$130.00 under § 1.17(c) is enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Dated: June 5, 2006

By: Salvatore J. Arr

Reg. No. 46,063

Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marci⁷ ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF SOLANGE CHAMARET (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Slaman Date: 24-05-05

2

Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re	App	lication	of:
-------	-----	----------	-----

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF CLAUDINE AXLER-BLIN (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

4. D. Carl

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: <u>clandine Axler</u>
Date: <u>26 Mai 2006</u>

. 2

CENTRAL Application No. 08/475,822

Filed: June 7, 1995

JUN 0 5 2006

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOISE REY (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Rv.

Date:

2

JUN 0 5 2006 W

U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF MARIE-THERESE NUGEYRE (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:

Date: <u>May</u> 29 2006

2

JUN 0 5 2006 W

U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al. Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85):

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

March ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND

PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT ON BEHALF OF JACQUELINE GRUEST (Being Added As An Inventor)

I, JACQUES GRUEST, am the heir of the estate of JACQUELINE GRUEST, who is deceased.

I have been informed that Jacqueline Gruest was not named as an inventor in application Serial No. 08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I have been informed that a copy of claims 47, 51, and 52 is attached hereto.

I have been informed that claims 47, 51, and 52 were added to U.S. application Serial No. 08/475,822 to claim previously unclaimed subject matter.

I have been informed that Jacqueline Gruest is being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that the addition of Jacqueline Gruest as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

On information and belief, the inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on the part of Jacqueline Gruest.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

ACQUES GRUEST

Heir of the Estate of Jacqueline Gruest

Date: 25.05-200

Patent Application No. 08/475,822

Inventors: Marc ALIZON et al. Div. of 07/158,652 (02/22/88); Div. of 06/771,248 (08/30/85; CIP of 07/999,410 (12/31/92); Cont. of 07/499,210 (03/19/90); Cont. of 06/771,230 (08/30/85); CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

) Group Art Unit: 1637
) Examiner: Jeffrey N. Fredman
) Confirmation No.: 4214

For: CLONED DNA SEQUENCES
RELATED TO THE GENOMIC RNA
OF LYMPHADENOPATHYASSOCIATED VIRUS (LAV) AND
PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF CHARLES DAUGUET (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No. 08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Chals Danguet

Date: 16 Mai 2006.

7.1787 U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al. Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.

Jeffrey N. Fredman



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc ¹ ALIZON et al.) Group Art Unit: 1637
Application No.: 08/475,822) Examiner: Jeffrey N. Fr
Filed: June 7, 1995) Confirmation No.: 4214

For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF WILLY ROZENBAUM (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No. 08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Crewsour.

Date: 25 Pay look

2

Dan his go



U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85); CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

March ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOIS BRUN-VEZINET (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

*

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 30/05/06





U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88):

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF CHRISTINE ROUZIOUX (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

Land on

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:

Date:

U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000



- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
- 52. The method of claim 51, further comprising detecting the HIV-1 RNA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marc' ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND

PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF LUC MONTAGNIER (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF JEAN-CLAUDE CHERMANN (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Jean. Claude Chermann

Date: Nay 26 2 06





U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000

- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

Marc ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOISE BARRE-SINOUSSI (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:

Date

05.24.2006

U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000



- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
- 52. The method of claim 51, further comprising detecting the HIV-1 RNA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

March ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES
RELATED TO THE GENOMIC RNA
OF LYMPHADENOPATHYASSOCIATED VIRUS (LAV) AND
PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

STATEMENT OF ROBERT C. GALLO (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Robert C. Sollo Date: May 31, 06



U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000



- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

) Group Art Unit: 1637

March ALIZON et al.

) Examiner: Jeffrey N. Fredman

Application No.: 08/475,822

) Confirmation No.: 4214

Filed: June 7, 1995

)

For: CLONED DNA SEQUENCES
RELATED TO THE GENOMIC RNA
OF LYMPHADENOPATHYASSOCIATED VIRUS (LAV) AND
PROTEINS ENCODED BY SAID
LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF MIKULAS POPOVIC (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.



I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Mikeles - Vyur,

Date: June 1, 2006

U.S. Patent Application No. 08/475,822

Filed: June 7, 1995

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000



- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:

March ALIZON et al.

Application No.: 08/475,822

Filed: June 7, 1995

For: CLONED DNA SEQUENCES

RELATED TO THE GENOMIC RNA

OF LYMPHADENOPATHY-

ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

LAV GENOMIC RNA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT OF MANGALASSERIL G. SARNGADHARAN (Being Added As An Inventor)

I have read U.S. application Serial No. 08/475,822.

I am informed that I was not named as an inventor in application Serial No.

08/475,822 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/475,822 have been amended by adding claims 47, 51, and 52 to the application.

I am informed that a copy of claims 47, 51, and 52 is attached hereto.

I understand that I am being added as an inventor to U.S. application Serial No. 08/475,822.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/475,822 is necessitated by the amendment of the claims by adding claims 47, 51, and 52 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 47, 51, and 52 to U.S. application Serial No. 08/475,822 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Mangalassenl G. Sarngadharan

Date: June 4, 2006





Inventors: Marc ALIZON et al. Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85;

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont. of 06/771,230 (08/30/85); CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (012/05/83)

DI No. 84-37

Our Reference: 03495.0010-24000



- 47. An *in vitro* diagnostic method for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1, and
 - (b) detecting HIV-1 nucleic acid present in said supernatant.
- 51. A method for preparing HIV-1 RNA for detecting the presence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:
 - (a) providing a biological fluid comprising HIV-1 infected cells;
 - (b) preparing a cell-free supernatant from the biological fluid; and
 - (c) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.
 - 52. The method of claim 51, further comprising detecting the HIV-1 RNA.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:
March ALIZON et al.
Application No.: 08/475,822
Filed: June 7, 1995
For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF LYMPHADENOPATHY- ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

LAV GENOMIC RNA

Sir:

CONSENT OF ASSIGNEE INSTITUT PASTEUR TO AMENDMENT OF INVENTORSHIP

Institut Pasteur, duly organized under the laws of France and having its principal place of business at 28, rue du Docteur Roux, 75724 Paris Cedex 15, France, as an Assignee of the above-identified application, does hereby consent to amendment of inventorship from the inventive entity:

Marc Alizon Pierre Sonigo Simon Wain-Hobson Stewart Cole Oliver Danos to the inventive entity:

Solange Chamaret
Claudine Axler-Blin
Françoise Rey
Marie-Therese Nugeyre
Jacqueline Gruest
Charles Dauguet
Willy Rozenbaum
Christine Rouzioux
François Brun-Vezinet
Luc Montagnier
Jean-Claude Chermann
Françoise Barre-Sinoussi
Robert C. Gallo
Mikulas Popovic
Mangalasseril G. Sarngadharan

The undersigned is authorized to act on behalf of the Assignee, Institut Pasteur.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

By: Houting
Name: Alice Dautry
Title: President
For Assignee: Institut Pasteur

Dated: ______



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1637

Confirmation No.: 4214

Examiner: Jeffrey N. Fredman

In re Application of:
March ALIZON et al.
Application No.: 08/475,822
Filed: June 7, 1995
For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF LYMPHADENOPATHY- ASSOCIATED VIRUS (LAV) AND PROTEINS ENCODED BY SAID

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

LAV GENOMIC RNA

Sir:

CONSENT OF ASSIGNEE THE UNITED STATES OF AMERICA TO AMENDMENT OF INVENTORSHIP

The United States of America as represented by the Secretary of the Department of Heath and Human Services, having its principal place of business at 900 Rockville Pike, Bethesda, Maryland 20892, as an Assignee of the above-identified application, does hereby consent to amendment of inventorship from the inventive entity:

Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Stewart Cole
Oliver Danos

to the inventive entity:

Robert C. Gallo
Mikulas Popovic
Mangalasseril G. Sarngadharan
Solange Chamaret
Claudine Axler-Blin
Françoise Rey
Marie-Therese Nugeyre
Jacqueline Gruest
Charles Dauguet
Willy Rozenbaum
Christine Rouzioux
François Brun-Vezinet
Luc Montagnier
Jean-Claude Chermann
Françoise Barre-Sinoussi

The undersigned is authorized to act on behalf of the Assignee, the United States of America as represented by the Secretary of the Department of Heath and Human Services.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Name TACK SPIEGEL (REG# 34, 477)
Title SELVOR ADVISOR POR TECHNOLOGY TRANSFER OPERATIONS

For Assignee: The United States of America

as represented by the

Secretary of the Department of Health and Human Services.

Dated: JUNES, 206

1110249